Anticancer Drugs Ixazomib Oncology Pharmacology Physiotherapy

Ixazomib (Mechanism of Action)

In this article we will discuss Ixazomib (Mechanism of Action)

In this article, we will discuss Ixazomib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model.


Cardiac Electrophysiology
Ixazomib did not prolong the QTc interval at clinically relevant exposures based on
pharmacokinetic-pharmacodynamic analysis of data from 245 patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.